Soquelitinib not checked
Corvus Pharmaceuticals, Inc. · CPI-818
FollowEvery change as it happens, and a Monday email
Trials
4 active
5 in total · 1 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Soquelitinib 200 mg tablets will be taken by mouth two times a day”In the company’s words, NCT06561048 on ClinicalTrials.gov
- Tested for
- Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Atopic Dermatitis and 5 more
- Main trialPhase 3
- “A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).”In the company’s words, NCT06561048 on ClinicalTrials.gov
- Other names
- CPI-818
Other drugs for Peripheral T-Cell Lymphoma, Not Otherwise Specified
- DuvelisibSecuraBio · Phase 3
- GolcadomideCelgene · Phase 1/2
- ARV-393Arvinas Inc. · Phase 1
- FenretinideSciTech Development, Inc. · Phase 1
Coming up4
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2027 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | |
| Phase 2Recruiting | Jun 2027 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | |
| Phase 1Active, not recruiting | 30 Dec 2026 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | |
| Phase 1Recruiting | Dec 2027 | Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa | |
| Phase 1Completed | 28 Jan 2026 | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026